Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H31NO3.C6H8O7 |
| Molecular Weight | 525.5886 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC(=O)CC(O)(CC(O)=O)C(O)=O.CCN(CC)CCOCCOC(=O)C1(CCCC1)C2=CC=CC=C2
InChI
InChIKey=AKJDEXBCRLOVTH-UHFFFAOYSA-N
InChI=1S/C20H31NO3.C6H8O7/c1-3-21(4-2)14-15-23-16-17-24-19(22)20(12-8-9-13-20)18-10-6-5-7-11-18;7-3(8)1-6(13,5(11)12)2-4(9)10/h5-7,10-11H,3-4,8-9,12-17H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
| Molecular Formula | C20H31NO3 |
| Molecular Weight | 333.465 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C6H8O7 |
| Molecular Weight | 192.1235 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: http://www.rxwiki.com/pentoxyverineCurator's Comment: Description was created using several sources including:
http://www.ncbi.nlm.nih.gov/pubmed/3768695 |
http://www.ncbi.nlm.nih.gov/pubmed/8057277 |
https://www.drugs.com/cdi/solotuss-suspension.html | http://www.drugsupdate.com/generic/view/1197/Pentoxyverine
Sources: http://www.rxwiki.com/pentoxyverine
Curator's Comment: Description was created using several sources including:
http://www.ncbi.nlm.nih.gov/pubmed/3768695 |
http://www.ncbi.nlm.nih.gov/pubmed/8057277 |
https://www.drugs.com/cdi/solotuss-suspension.html | http://www.drugsupdate.com/generic/view/1197/Pentoxyverine
Pentoxyverine is a non-opioid antitussive used to prevent cough caused by common cold. It is used as an active ingredient of several oral over-the-counter cough suppressants alone or in combination with other medications, especially decongestants. Certuss is a combination of pentoxyverine and guaifenesin. Pentoxyverine is FDA pregnancy category C drug. Known as anticonvulsant, and spasmolytic agent.
CNS Activity
Sources: http://www.ncbi.nlm.nih.gov/pubmed/3768695
Curator's Comment: Carbetapentane bindinding with high affinity to the in the brain of rats potentiated the effects of the prototypic antiepileptic drug diphenylhydantoin.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL4153 Sources: http://www.ncbi.nlm.nih.gov/pubmed/14691051 |
75.0 nM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | Unknown Approved UseUnknown |
Doses
| Dose | Population | Adverse events |
|---|---|---|
30 mg 3 times / day multiple, oral (mother), breasteeding (infant) Overdose Dose: 30 mg, 3 times / day Route: oral (mother), breasteeding (infant) Route: multiple Dose: 30 mg, 3 times / day Sources: |
healthy, infant |
Disc. AE: Respiratory failure... AEs leading to discontinuation/dose reduction: Respiratory failure (acute, 1 patient) Sources: |
100 mg 1 times / day multiple, oral Highest studied dose Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: |
unhealthy |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Respiratory failure | acute, 1 patient Disc. AE |
30 mg 3 times / day multiple, oral (mother), breasteeding (infant) Overdose Dose: 30 mg, 3 times / day Route: oral (mother), breasteeding (infant) Route: multiple Dose: 30 mg, 3 times / day Sources: |
healthy, infant |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Tox targets
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/19034038/ Page: 1.0 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Quantification of pentoxyverine citrate in human plasma by LC-ESI/MS method and its application]. | 2009-12 |
|
| Effects of common antitussive drugs on the hERG potassium channel current. | 2008-12 |
|
| Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use; final rule for over-the-counter antitussive drug products; technical amendment. Final rule, technical amendment. | 2007-11-30 |
|
| Study on the enhancement of Ru(bpy)3(2+) electrochemiluminescence by nanogold and its application for pentoxyverine detection. | 2005-12 |
|
| Anti-proliferative activity of haloperidol in B16 mouse and human SK-MEL-28 melanoma cell lines. | 2005-10 |
|
| Capacitive sensors using electropolymerized o-phenylenediamine film doped with ion-pair complex as selective elements for the determination of pentoxyverine. | 2004-06-17 |
|
| A non-potentiometric sensing method for the determination of pentoxyverine with PQC sensors based on ion-pair complexes. | 2001-12 |
|
| Propiverine-induced Parkinsonism: a case report and a pharmacokinetic/pharmacodynamic study in mice. | 2000-05 |
Sample Use Guides
Pentoxyverine citrate or hydrochloride salts for adults up to 180 mg/day can be prescribed in divided doses. Pentoxyverine should be taken with food
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/14691051
1-5 mg/kg inhibited citric-acid-induced cough in guinea-pigs
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:22:21 GMT 2025
by
admin
on
Mon Mar 31 18:22:21 GMT 2025
|
| Record UNII |
4SH0MFJ5HJ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C66917
Created by
admin on Mon Mar 31 18:22:21 GMT 2025 , Edited by admin on Mon Mar 31 18:22:21 GMT 2025
|
||
|
CFR |
21 CFR 216.24
Created by
admin on Mon Mar 31 18:22:21 GMT 2025 , Edited by admin on Mon Mar 31 18:22:21 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
283547
Created by
admin on Mon Mar 31 18:22:21 GMT 2025 , Edited by admin on Mon Mar 31 18:22:21 GMT 2025
|
PRIMARY | RxNorm | ||
|
4SH0MFJ5HJ
Created by
admin on Mon Mar 31 18:22:21 GMT 2025 , Edited by admin on Mon Mar 31 18:22:21 GMT 2025
|
PRIMARY | |||
|
245-449-5
Created by
admin on Mon Mar 31 18:22:21 GMT 2025 , Edited by admin on Mon Mar 31 18:22:21 GMT 2025
|
PRIMARY | |||
|
23142-01-0
Created by
admin on Mon Mar 31 18:22:21 GMT 2025 , Edited by admin on Mon Mar 31 18:22:21 GMT 2025
|
PRIMARY | |||
|
DBSALT001543
Created by
admin on Mon Mar 31 18:22:21 GMT 2025 , Edited by admin on Mon Mar 31 18:22:21 GMT 2025
|
PRIMARY | |||
|
CHEMBL73234
Created by
admin on Mon Mar 31 18:22:21 GMT 2025 , Edited by admin on Mon Mar 31 18:22:21 GMT 2025
|
PRIMARY | |||
|
SUB03695MIG
Created by
admin on Mon Mar 31 18:22:21 GMT 2025 , Edited by admin on Mon Mar 31 18:22:21 GMT 2025
|
PRIMARY | |||
|
4SH0MFJ5HJ
Created by
admin on Mon Mar 31 18:22:21 GMT 2025 , Edited by admin on Mon Mar 31 18:22:21 GMT 2025
|
PRIMARY | |||
|
C76472
Created by
admin on Mon Mar 31 18:22:21 GMT 2025 , Edited by admin on Mon Mar 31 18:22:21 GMT 2025
|
PRIMARY | |||
|
m3065
Created by
admin on Mon Mar 31 18:22:21 GMT 2025 , Edited by admin on Mon Mar 31 18:22:21 GMT 2025
|
PRIMARY | Merck Index | ||
|
757833
Created by
admin on Mon Mar 31 18:22:21 GMT 2025 , Edited by admin on Mon Mar 31 18:22:21 GMT 2025
|
PRIMARY | |||
|
C018861
Created by
admin on Mon Mar 31 18:22:21 GMT 2025 , Edited by admin on Mon Mar 31 18:22:21 GMT 2025
|
PRIMARY | |||
|
100000090449
Created by
admin on Mon Mar 31 18:22:21 GMT 2025 , Edited by admin on Mon Mar 31 18:22:21 GMT 2025
|
PRIMARY | |||
|
DTXSID10177717
Created by
admin on Mon Mar 31 18:22:21 GMT 2025 , Edited by admin on Mon Mar 31 18:22:21 GMT 2025
|
PRIMARY | |||
|
90010
Created by
admin on Mon Mar 31 18:22:21 GMT 2025 , Edited by admin on Mon Mar 31 18:22:21 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |